In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America

被引：30

作者：

Diekema, DJ ^{[1
]}

Pfaller, MA ^{[1
]}

Messer, SA ^{[1
]}

Houston, A ^{[1
]}

Hollis, RJ ^{[1
]}

Doern, GV ^{[1
]}

Jones, RN ^{[1
]}

机构：

[1] Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 09期

关键词：

D O I：

10.1128/AAC.43.9.2236

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates of Candida spp, collected from SENTRY participating hospitals during 1997 and 1998, Overall, BMS-207147 was the most active azole against all Candida spp, While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp, that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.

引用

页码：2236 / 2239

页数：4

共 12 条

[1] New azole antifungals.: 3.: Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
Bartroli, J
Turmo, E
Algueró, M
Boncompte, E
Vericat, ML
Conte, L
Ramis, J
Merlos, M
García-Rafanell, J
Forn, J
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (11) : 1869 - 1882
[2] ESPINELINGROFF A, 1998, 38 INT C ANT AG CHEM, P452
[3] ESPINELINGROFF A, 1998, 38 INT C ANT AG CHEM, P271
[4] Fung-Tomc JC, 1998, ANTIMICROB AGENTS CH, V42, P313
[5] Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of Aspergillosis, Candidiasis, and Cryptococcosis
Hata, K
Kimura, J
Miki, H
Toyosawa, T
Moriyama, M
Katsu, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2243 - 2247
[6] In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
Hata, K
Kimura, J
Miki, H
Toyosawa, T
Nakamura, T
Katsu, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2237 - 2242
[7] National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[8] In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
Pfaller, MA
Messer, SA
Gee, S
Joly, S
Pujol, C
Sullivan, DJ
Coleman, DC
Soll, DR
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) : 870 - 872
[9] In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
Pfaller, MA
Messer, SA
Hollis, RJ
Jones, RN
Doern, GV
Brandt, ME
Hajjeh, RA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) : 3242 - 3244
[10] Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections
Rex, JH
Pfaller, MA
Galgiani, JN
Bartlett, MS
EspinelIngroff, A
Ghannoum, MA
Lancaster, M
Odds, FC
Rinaldi, MG
Walsh, TJ
Barry, AL
[J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) : 235 - 247

← 1 2 →